RYANODEX remains approved for the treatment of malignant hyperthermia in conjunction with appropriate supportive measures, and for the prevention of malignant hyperthermia in patients at high risk.
To the Editor: Malignant hyperthermia (MH) is a rare but potentially fatal, inherited skeletal muscle disorder that is mostly induced by the ingestion of the depolarizing relaxant, i.e., succinylcholine or volatile anesthetics.[sup][1] Its incidence is reportedly 1/5000 to 1/100,000 in general anesthesia patients, and children seem to be more susceptible than adults.[sup][2] According to MH treatment guidelines of the Malignant Hyperthermia Association of the United States (MHAUS) and European Malignant Hyperthermia Group (EMHG), dantrolene should be administered as soon as possible in suspected case.[sup][3],[4] Unfortunately, dantrolene is not readily available worldwide.
NMS is a diagnosis of exclusion, so it should be differentiated from other conditions, including infection of central nervous system (CNS), agitated delirium, malignant catatonia, serotonin syndrome, malignant hyperthermia (2,10).
All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.